Drug Profile


Alternative Names: NG 273

Latest Information Update: 06 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Developer Ligand Pharmaceuticals
  • Class Imidazoles; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action GABA A alpha 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Insomnia; Schizophrenia

Most Recent Events

  • 06 Jul 2010 Development discontinued during 2008
  • 14 Jul 2008 Suspended - Phase-II/III for Insomnia in USA (PO)
  • 12 Jun 2008 Final efficacy data from two phase II trials in Insomnia presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top